AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Plain-language summary
This trial is testing AZD3470 for patients with angioimmunoblastic T-cell lymphoma (AITL) or TFH lymphomas, anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. Patients are randomly assigned to different treatment groups. This trial is available at 8 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 12 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
AZD3470 (DRUG): AZD3470 is a novel, potent and selective, second-generation, Methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5. | Pembrolizumab (DRUG): Pembrolizumab (CAS nr: 1374853-91-4 )
AZD3470, Pembrolizumab
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details